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Abstract
Background Recent randomized clinical trials (RCTs)
demonstrated the efficacy of mechanical thrombectomy
using stent-retrievers in patients with acute ischemic
stroke (AIS) with large vessel occlusions; however, it
remains unclear if these results translate to a real-world
setting. The TREVO Stent-Retriever Acute Stroke (TRACK)
multicenter Registry aimed to evaluate the use of the
Trevo device in everyday clinical practice.
Methods Twenty-three centers enrolled consecutive AIS
patients treated from March 2013 through August 2015
with the Trevo device. The primary outcome was deﬁned
as achieving a Thrombolysis in Cerebral Infarction (TICI)
score of ≥2b. Secondary outcomes included 90-day
modified Rankin Scale (mRS), mortality, and symptomatic
intracranial hemorrhage (sICH).
Results A total of 634patients were included. Mean
age was 66.1±14.8 years and mean baseline NIH Stroke
Scale (NIHSS) score was 17.4±6.7; 86.7% had an
anterior circulation occlusion. Mean time from symptom
onset to puncture and time to revascularization were
363.1±264.5 min and 78.8±49.6 min, respectively.
80.3% achieved TICI ≥2b. 90-day mRS ≤2 was achieved
in 47.9%, compared with 51.4% when restricting the
analysis to the anterior circulation and within 6 hours
(similar to recent AHA/ASA guidelines), and 54.3% for
those who achieved complete revascularization. The 90day mortality rate was 19.8%. Independent predictors
of clinical outcome included age, baseline NIHSS, use of
balloon guide catheter, revascularization, and sICH.
Conclusion The TRACK Registry results demonstrate
the generalizability of the recent thrombectomy RCTs in
real-world clinical practice. No differences in clinical and
angiographic outcomes were shown between patients
treated within the AHA/ASA guidelines and those treated
outside the recommendations.

Introduction

To cite: Zaidat OO,
Castonguay AC, Nogueira RG,
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2018;10:516–524.
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Following the publication of multiple positive
consecutive randomized clinical trials (RCTs),
mechanical thrombectomy is now considered the
standard of care for acute ischemic stroke (AIS)

due to large vessel occlusion (LVO).1–11 Improved
patient selection criteria and significant technical
advances leading to a higher rate of meaningful
revascularization were the main advances that led
to a better clinical outcome than the first-generation thrombectomy devices.12 13
However, RCTs are limited by the restrictive
nature of study design in many aspects, such as
inclusion and exclusion criteria, center selection,
and operator experience; therefore, the results
may not be generalizable to real-world practice.
Post-marketing clinical registries allow for more
inclusive criteria by including a range of clinical
sites, operators, and varying patient populations,
which provides valuable information on the generalizability and reproducibility of RCTs and additional opportunities to explore clinical hypotheses
for patients treated outside these RCTs.14–16
The first stent-retriever device to be introduced
to the USA was the Solitaire device, which has
been shown to be as effective in achieving similar
revascularization and clinical outcome in real-life
post-marketing experience. Relatively comparable
safety and efficacy outcomes were demonstrated in
the North American Solitaire Acute ischemic stroke
study (NASA Registry) and other post-marketing
clinical studies.14–16 However, there is no published
large-scale post-marketing investigator-initiated
registry for the second FDA-approved stent-retriever, the Trevo device.
The TREVO Stent-Retriever Acute Stroke
(TRACK) Registry is, to date, the largest investigator-initiated independent US post-marketing
registry evaluating the real-life clinical experience
of the Trevo device in 634 patients with AIS. In
addition to comparing the results with the TREVO2
RCT to assess for generalizability, we also evaluated the safety and efficacy in those treated outside
the AHA/ASA-published endovascular treatment
guideline.2

Methods

Twenty-three US centers submitted retrospective
and prospective data on consecutive patients with
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AIS treated from March 2013 through August 2015 with the
Trevo device as the first mechanical thrombectomy treatment
method to restore blood flow for LVO. Patients aged <18
years and those who were not treated with Trevo as the firstpass device were excluded. Sites submitted de-identified patient
level data (demographic, clinical, procedural, and angiographic).
Institutional review board approval was obtained at each site.
Mercy Health St Vincent Hospital (Toledo, Ohio, USA) served
as the coordinating center for TRACK.

TRACK angiographic and clinical outcomes

The primary angiographic outcome was deﬁned as achieving a
modified Thrombolysis in Cerebral Infarction (mTICI) score
of ≥2b at the end of the procedure.9 14 Secondary outcomes
included revascularization rate (complete revascularization to
TICI 3), symptomatic intracranial hemorrhage (sICH) on the
24 hours follow-up head CT, modiﬁed Rankin Scale (mRS) score
and mortality at 90 days. sICH was deﬁned as any parenchymal
hematoma, subarachnoid hemorrhage, or intraventricular
hemorrhage associated with worsening of the National Institutes of Health Stroke Scale (NIHSS) score by ≥4 points within
24 hours. Primary and secondary outcomes were then compared
with the TREVO2 trial to assess for reproducibility of the results
in the TRACK Registry.
The full TRACK cohort was further dichotomized into
patients who met the AHA/ASA recommendations guidelines2
(treated ≤6 hours of symptoms onset, intravenous tissue plasminogen activator (IV-tPA) (if eligible), NIHSS ≥6, anterior
circulation occlusion only (except for ASPECT score, which was
not collected in the TRACK)) and the non-AHA/ASA population.

Figure 1

Statistical analysis

Statistical analyses were performed using JMP V.13 (SAS institute, Cary, North Carolina, USA). Fisher exact or χ2 tests were
used for categorical variables and the Student’s t-test/F test for
continuous variables.
Baseline demographic, angiographic, and clinical outcome
data were analyzed for the full TRACK cohort and compared
with TREVO2 data. Key system of care and time metrics were
presented for the full TRACK cohort. True First Pass Effect
(tFPE), defined as TICI 3 on the first pass with no use of rescue
therapy, was also evaluated.
Univariate analysis was also performed between the AHA/ASA
and non-AHA/ASA groups with the TRACK cohort to compare
baseline features and angiographic and clinical outcomes. For all
analyses, variables with a p value ≤0.05 and clinically relevant
factors were entered into a multivariate stepwise logistic regression model to determine predictors of clinical outcome and/or
mortality.

Results
Full TRACK cohort results

A total of 634 consecutive patients were enrolled into the
TRACK Registry (figure 1). Five patients were excluded from the
final analysis (2 were <18 years of age and 3 were not treated
with Trevo as the first device).

Demographic and baseline features

Baseline demographics are shown in table 1. Mean baseline
NIHSS was higher in TREVO2 (18.3±5.3) than in TRACK

TRACK Registry Flow Chart.
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Table 1
cohorts

Baseline and procedural characteristics of the TRACK Registry compared with TREVO2 and TRACK AHA/ASA and non-AHA/ASA subTRACK
(n=629)
N (%)

TREVO2
(n=88)
N (%)

p Value
TRACK versus
TREVO2

TRACK-AHA/ASA
(n=157)
N (%)

TRACK-non-AHA/ASA p Value
(n=450)
AHA/ASA versus
N (%)
non-AHA/ASA

Demographics
 Age (years), mean (SD)

66.1 (14.8)

67.4 (13.9)

0.24

 Age >80

114 (18.1)

NA

NA

 Gender (female)

305 (48.3)

48 (55)

0.3

 Race (white)

424 (68.1)

NA

 Hypertension

473 (75.0)

 Atrial fibrillation
 Diabetes mellitus

64.9 (15.5)

66.5 (14.5)

0.24

27 (17.2)

85 (18.9)

0.72

71 (45.2)

220 (48.9)

0.46

NA

101 (64.3)

305 (69.0)

0.09

67 (76)

0.04

124 (79.0)

335 (74.4)

0.28

247 (39.2)

42 (48)

0.13

56 (35.7)

184 (41.0)

0.26

161 (25.5)

33 (38)

0.02

41 (26.1)

117 (26.0)

1.00

 Hyperlipidemia

314 (49.8)

55 (63)

0.03

76 (48.4)

229 (50.2)

0.64

 Smoking history

154 (24.5)

37 (42)

0.001

40 (25.5)

112 (25.0)

0.92

 Coronary artery disease

146 (29.4)

29 (33)

0.1

35 (28.2)

104 (29.6)

0.82

0 (0,5)

0 (0,1)

0 (0,1)

0 (0,5)

Vascular risk factors

Clinical presentation
 Baseline mRS (median) (min, max)

17.4 (6.7)

18.3 (5.3)

0.04

18.0 (5.8)

17.2 (6.9)

0.19

 All MCA segments

434 (68.9)

67 (76)

0.002

118 (75.2)

298 (66.4)

0.06

 M1

344 (54.6)

53 (60)

0.03

118 (75.2)

209 (70.1)

0.0001

 M2

84 (13.3)

14 (16)

0.5

0 (0)

83 (27.9)

0.0001

0 (0)

0.2

14 (16)

1.0

7 (8)

0.2

 Initial NIHSS, mean (SD)
Occlusion site

 M3

6 (1.0)

 ICA

100 (15.9)

 Vertebrobasilar circulation
 Anterior circulation

84 (12.7)
546 (86.7)

0 (0)
39 (24.8)
0 (0)

6 (2.0)

0.34

55 (12.3)

0.0003

84 (18.7)

0.0001
0.0001

81 (92)

0.2

157(100)

365 (81.3)

Initial systolic BP, mean (SD)

144.9 (26.6)

NA

NA

145.9 (28.1)

144.7 (26.2)

Initial diastolic BP, mean (SD)

78.2 (19.2)

NA

NA

78.6 (20.9)

78.1 (18.6)

0.63

IV tPA

321 (51.2)

51 (58)

0.22

157 (100)

164 (34.9)

0.0001

Hospital transfer

315 (50.0)

NA

NA

62 (39.5)

237 (52.8)

0.005

363.1 (264.5)

276 (90)

0.00

413.8 (287.7)

<0.0001

 General anesthesia

394 (62.4)

72 (82)

0.004

89 (56.7)

284 (63.1)

0.2

 Regional aspiration

142 (22.6)

NA

NA

44 (30.3)

98 (23.6)

0.12

 IA tPA

130 (20.7)

NA

NA

46 (29.3)

83 (18.5)

0.006

 Balloon guide catheter

298 (47.3)

NA

NA

84 (53.5)

206 (45.9)

0.08

0.68

Procedural factors
 Time from onset to puncture (min), mean (SD)

217.5 (67.8)

Bold type indicates statistical significance.
AHA, American Heart Association; ASA, American Stroke Association; ICA, internal carotid artery; mRS, modified Rankin Scale; MCA, middle cerebral artery; NIHSS, National
Institutes of Health Stroke Scale; tPA, tissue plasminogen activator.

(17.4±6.7) (p=0.04). TRACK had a significantly lower proportion of patients with diabetes, hyperlipidemia, and smoking
history. The majority of patients presented with an anterior
circulation occlusion (86.7%), with less middle cerebral artery
(MCA) occlusion in TRACK compared with TREVO2 (68.9%
vs 76%, p=0.0002).

TRACK time metrics

Key time metrics in TRACK are presented in figure 2A and show
a median last known well to presentation at the treating hospital
door of 160 min, a door to puncture time of 118 min, and final
puncture to successful recanalization to TICI ≥2b of 67 min.
518

The majority of TRACK patients (48%) had their puncture
within 4.5 hours from onset while 15% had their puncture at
4.5–6 hours (figure 2B).

Primary angiographic outcomes

The TRACK operator-adjudicated revascularization rates of
TICI ≥2a, TICI ≥2b, and TICI 3 were significantly higher than
in TREVO2 (92.8%, 80.3%, 44.5% and 85%, 68%, 14% in
TRACK and TREVO2, respectively) (table 2). The TICI ≥2b
revascularization rate post-Trevo device use only was 68.8% in
TRACK versus 68% in TREVO2.

Zaidat OO, et al. J NeuroIntervent Surg 2018;10:516–524. doi:10.1136/neurintsurg-2017-013328

Ischemic stroke

Figure 2 TRACK Registry key time metrics and outcomes. (A) Key time metrics. (B) Distribution of patients according to Tme of Onset to Groin
puncture (TOG) and percentage of good clinical outcome in each stratum. (C) Distribution of 90-day modified Rankin Scale (mRS) scores in the TRACK
Registry, AHA/ASA, non-AHA/ASA, and true First Pass Effect (tFPE) cohorts. The bar indicates patients with a good clinical outcome (mRS ≤2). tFPE is
defined as TICI 3 on the first pass with no use of rescue therapy.

The mean number of passes in TRACK was 1.9±1.2
compared with 2.4±1.4 in TREVO2 (p=0.002). The majority
of TRACK cases (45.6%) were treated using a single device pass.

Rescue therapy was used in 21.5% of TRACK patients. Operator-adjudicated rates of distal embolization and embolization into
new territory in TRACK were 23% and 4.5%, respectively.
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Table 2

Clinical and angiographic outcomes of the TRACK Registry versus TREVO2, AHA/ASA and non-AHA/ASA sub-cohorts

TRACK (n=629)
N (%)

TREVO2
(n=88) N(%)

p Value TRACK
versus TREVO2

*TRACK-AHA/ASA
(n=157) N (%)

*p Value
*TRACK-non-AHA/ASA AHA/ASA
(n=450)
versus nonN (%)
AHA/ASA

Clinical outcome
 mRS ≤2 at 90 days

277 (47.9)

34 (40)

0.2

75 (51.4)

 NIHSS at discharge, mean (SD)

17.4 (6.7)

NA

NA

11.3 (11.3)

11.3 (11.1)

1.00

NIHSS at 90 days, mean (SD)

18.1 (18.7)

NA

NA

13.7 (16.6)

19.9 (19.3)
Anterior circulation
only: 18.9 (19)

0.04
0.1

Mortality at 90 days

106 (19.8)

29 (33)

0.01

44 (7.1)

4 (4.5)

0.4

sICH

19 (14.1)

193 (46.7)
0.34
Anterior circulation only: 0.49
158/333 (47.5%)

85 (22.2)
0.05
Anterior circulation only: 0.22
59 (19.3)

8 (5.2)

35 (8.0)

0.28

Angiographic outcomes
 TIMI ≥2

564 (89.7)

NA

NA

141 (89.8)

400 (89.6)

1.0

 TICI ≥2a

584 (92.8)

73 (85)

0.0004

146 (93.0)

415 (92.9)

1.0

 TICI ≥2b

505 (80.3)

60 (68)*

0.005

128 (81.5)

360 (80.4)

0.81

 TICI 2a

79 (12.6)

19 (22)*

0.004

19 (12.1)

60 (12.7)

0.89

 TICI 2b

225 (35.8)

48 (54)*

0.001

45 (28.7)

180 (38.1)

0.03

 TICI 3

280 (44.5)

12 (14)*

<0.05

82 (52.2)

198 (41.9)

0.03

 Distal embolization

112 (23.0)

NA

NA

24 (19.4)

81 (23.7)

0.38
0.042

 Embolization into new territory

20 (4.5)

NA

NA

10 (8.3)

9 (2.9)

 No of passes, mean (SD)

1.9 (1.2)

2.4 (1.4)

0.002

2.0 (1.1)

1.9 (1.2)

0.40

 1

272 (45.6)

NA

NA

61 (41.2)

201 (47.1)

0.22

 2

167 (28.2)

NA

NA

44 (29.7)

123 (27.5)

0.92

 3

112 (18.8)

NA

NA

34 (23.0)

78 (17.4)

0.23

 >3
 Use of rescue therapy

45 (7.5)
133 (21.5)

NA

NA

6 (4.1)

36 (8.0)

0.10

16 (18)

0.48

35 (22.9)

93 (21.0)

0.65

 Type of rescue therapy (65/133)
 Solitaire

29 (44.6)

 IA-tPA

28 (43.1)

 Aspiration

41 (63.1)

 Intracranial angioplasty

15 (23.1)

 Fluoroscopic time (min)

32.3 (22.9)

NA

NA

31.9 (21.2)

32.8 (23.8)

0.35

 Time of puncture to revascularization or end of
procedure (min), mean (SD)

78.8 (49.6)

NA

NA

77.1 (46.8)

79.2 (48.9)

0.64

*Core laboratory adjudicated.
Bold type indicates statistical significance.
AHA, American Heart Association; ASA, American Stroke Association, mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; sICH, symptomatic
intracranial hemorrhage; TICI, Thrombolysis In Cerebral Infarction; tPA, tissue plasminogen activator.

Primary clinical outcomes

Ninety-day clinical outcome data were available in 92%
(579/629). Good clinical outcome (defined as mRS ≤2 at 90
days) was achieved in 48% of TRACK patients (table 2 and
figure 2C). No difference in sICH rate was observed between
TRACK and TREVO2. The mortality rate was lower in TRACK
than in TREVO2 (19.8% vs 33%, p=0.01).
Finally, we assessed the rate of good clinical outcome in
those who achieved tFPE of TICI 3 without the use of adjunctive therapy (25%). This group achieved a higher rate of good
clinical outcome (54.3%) than the rate of 48% achieved for the
overall TRACK cohort (p<0.05) (figure 2C).
520

Predictors of clinical outcomes

On univariate analysis, the main predictors of good outcome
(mRS 0–2) were recanalization success, use of balloon guide
catheter (BGC), and tFPE, and predictors of poor outcome
(3–6 mRS) included age, NIHSS, hypertension, hyperlipidemia,
diabetes, procedure time, and sICH (figure 3). However, after
multivariate adjustment, the variables that remained as independent predictors of clinical outcome were age, initial NIHSS,
BGC, sICH, and tFPE.
Additionally, we performed unadjusted analyses of key clinical and technical factors known to influence mRS. Figure 4A–D
demonstrates an inverse correlation between clinical outcome
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Figure 3 Forest plot of univariate predictors of clinical outcome dichotomized as mRS 0–2. OR (95% CI) are depicted to the right of the figure. Red
and black bars indicate variables which are significant.

and age, baseline NIHSS, time to revascularization, and number
of passes. The highest probability of achieving mRS 0–2 is
patients of younger age with lower baseline NIHSS, shorter time
to revascularization, and fewer number of passes, while those
with advanced age, higher initial NIHSS, longer time to revascularization, and high number of passes had the greatest probability of achieving an mRS 4–6. These factors did not appear to
influence the probability of achieving mRS 3.

TRACK AHA and non-AHA subgroups

For the TRACK AHA and non-AHA cohort analysis, 22 cases
were excluded due to missing data necessary for classification
based on AHA/ASA guidelines; 157 and 450 patients met the
criteria for the AHA/ASA and non-AHA/ASA groups, respectively (figure 1).

Baseline variables

Given the exclusivity of anterior circulation lesions in the AHA/
ASA cohort, there was a statistical difference between the AHA/ASA
and non-AHA/ASA groups in the occlusion location (table 1). Mean
time from onset to puncture was different between the AHA/ASA
and non-AHA/ASA groups (217.5±67.8 min vs 413.8±287.7 min,
p<0.0001). IV-tPA use was 100% versus 34.9% in the AHA/ASA
and non-AHA/ASA cohorts, respectively. Patient transfer was more
common in the non-AHA/ASA group (53%, p=0.005). A higher
rate of IA thrombolytic utilization was noted in the AHA/ASA
group (29%, p=0.006).

Angiographic and technical outcomes

No difference was observed in revascularization success rates in
the AHA/ASA and non-AHA/ASA groups (table 2). However, a
significantly higher rate of TICI 3 was seen in the AHA/ASA

Zaidat OO, et al. J NeuroIntervent Surg 2018;10:516–524. doi:10.1136/neurintsurg-2017-013328

521

Ischemic stroke

Figure 4 (A–D) Probability of ordinal modified Rankin Scale (mRS) with key clinical and technical factors. Note the highest probability of mRS 1
with younger age, lower initial NIHSS, shorter revascularization time, and smaller number of passes; mRS 3 is not a discriminator. An inverse effect
was noted at the other extremes, with a higher probability of mRS 6 with older age, higher initial NIHSS, longer revascularization time, and higher
number of passes.

cohort. Embolization into new territory was higher in AHA/ASA
patients (8.3% vs 2.9%, p=0.04).

6 hour time window; however, these subgroups still had an
excellent angiographic and clinical outcome (table 2, figure 2b).

Clinical outcomes

Angiographic outcomes

The rate of good clinical outcome at 90 days (mRS ≤2) was
similar between the cohorts but mortality was higher in the
non-AHA/ASA group (table 2).

Discussion

To date, TRACK is the largest investigator-initiated, real-life,
post-marketing, clinical registry evaluating a total of 634 subjects
treated with Trevo as the first device for AIS secondary to LVO.
Results from the TRACK Registry supported similar angiographic and clinical outcomes as reported in TREVO2 RCTs and
the NASA Registry.9 10
A unique observation from this real-life registry is that a
large proportion of patients (74.1%) were treated outside the
recent AHA/ASA guidelines and recommendations for endovascular therapy. For example, 18.1% in the non-AHA/ASA group
were >80 years of age and 37% of patients were outside the
522

The final angiographic revascularization outcome (after all
devices and rescue therapy) of TICI ≥2b was higher in TRACK
than in TREVO2 (80.3% vs 68%).9 However, when comparing
the revascularization rate post-Trevo device use only, there was
no difference between the two cohorts (68.8% in TRACK versus
68% in TREVO2).9 When compared with the recently published
randomized trials, the rate of TICI 2b/3 is comparable with the
Solitaire-treated patients in the SEER pooled analysis (77%) and
with the HERMES mechanical thrombectomy group (71%).11 12
In our study, we observed a significantly higher proportion
of patients achieving near complete final revascularization
to TICI 3 (44.5% final and 37.4% post-Trevo only vs 14% in
TREVO2).9 The higher rate of near complete revascularization
may be explained by several factors. (1) In real-life experience
there is no limit to the number of passes that an operator can
attempt. (2) The rate of BGC use, proven since the TREVO2
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study to be associated with a higher rate of near complete revascularization, may be higher in the current registry (47.3% in
TRACK vs 44.1% in NASA, unavailable in TREVO2 study).15 17
(3) An improvement in operator learning and experience since
the approval of the device. (4) The combined approach of Trevo
device with local aspiration from a distal large-bore catheter,
which was used in approximately 23% of the cases.
Although potential for self-reporting bias of the angiographic
data is another valid reason for the higher rate of near complete
revascularization, TREVO2 showed that there was no difference between operator and core laboratory adjudication of the
recanalization.9
The self-reported rates of distal embolization and embolization into new territory were similar to those in the NASA
Registry (23% vs 16.4% and 4.5% vs 5.5%, respectively).10 The
rate of distal embolization correlated well with those who did
not achieve TICI 2b or higher, indicating possible persistent
downstream occlusion. The ability to accurately estimate the
rate of new embolization is limited by lack of complete baseline
angiographic assessment or availability of pre-intervention CT
angiographic data.

Clinical outcome

Despite the high rate of posterior circulation thrombectomy
(table 1) and percentage of patients who had an onset to puncture
time >6 hours (figure 2b), the rate of good clinical outcome in
the TRACK Registry was 47.9%, which compared well with the
rates in TREVO2 (40%) and with the NASA Registry (42%).9 10
In the TRACK AHA/ASA group the rate of a good clinical
outcome was 51.4%, which is similar to the rates of good clinical
outcome noted in the HERMES and SEER pooled analyses (46%
and 54%, respectively).11 12 The clinical outcome in TRACK was
also augmented to 54.3% in patients achieving tFPE to TICI 3
(figure 3), as shown in previous studies.17
The rates of sICH were similar in TRACK (7.1%), TREVO2
(4.1%), and NASA (9.9%).9 10 The numerical difference in
hemorrhage rate in TRACK versus TREVO2 may be related
to a more liberal inclusion of patients with severe strokes and
those outside the 8 hour time window. When patients with only
anterior circulation were evaluated, the rate of symptomatic
hemorrhage decreased to 5.2%, which is similar to the HERMES
pooled analysis of 4.4%.12
The mortality rate in TRACK was 19.8%, which is lower than
the reported rate of 33% in NASA.9 10 When examining the
mortality rate within the AHA/ASA guidelines-like group, the
mortality rate decreased to 14.4%, which compared well with
the 15.3% noted with the HERMES pooled analysis.12
Similar to other studies, recanalization, FPE, BGC, and MCA
clot location predicted a favorable outcome while age, procedure time, symptomatic hemorrhage, initial NIHSS and age were
predictors of a poor clinical outcome as depicted.18–20
An interesting observation was noted in the ordinal mRS
outcome of the key predictors of clinical outcome (figure 4). We
noted a higher likelihood of achieving mRS 1, followed by 2
then 0 with endovascular therapy, when the predictors favored
a good outcome (such as shorter onset to puncture time, younger
age, less severe baseline NIHSS, shorter revascularization time,
and fewer number of device attempts). mRS 6, followed by 4,
then 5 (in this order) were more likely to happen when these
factors were not favorable for a good clinical outcome. Interestingly, mRS 3 was flat with no slope and predication ability across
all these clinical variables.
Revascularization time (defined as puncture to TICI 2b)
metrics in TRACK showed a mean time of 78±49.6 min

compared with 77.1±46.8 min in NASA.10 This may be related
to individual patient variability between the two studies and may
be evaluated in the future in an individual patient-level pooled
analysis. An additional potential explanation is the difference in
centers participating in the two studies and their system of care
and local processes.

Limitations

TRACK has the inherent limitation of self-reported prospective and retrospective angiographic and clinical outcome data.
However, site and core laboratory-reported angiographic
outcomes in TREVO2 were similar. In addition, including all
consecutive patients and sample size may have reduced the selection bias.
Another limitation is the potential lack of precision in our
reported time metrics due to the retrospective nature of the data,
which could result in over/underestimation of time metrics (such
as the door to puncture and revascularization times).

Conclusion

Our real-life experience with the TREVO device demonstrated
the ability to mirror the recanalization, safety, and efficacy
outcomes obtained in the TREVO2, SEER, and HERMES
randomized clinical studies.
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